Monica Rinaldi gained her M.S. degree in biology with full award and residency in biotechnology with honors at the Sapienza University of Rome, Rome, Italy. From 1996 to 2001, she was appointed as an Assistant Professor of general pathology, Faculty of Medicine, and as a Professor of molecular biology with a degree in biomedical engineering, Faculty of Engineering (1999-2000) at the University of Rome Campus Bio-Medico, Rome, Italy. Since 2001, she has been a Research Scientist at the Department of BioMedicine, Italian National Research Council (CNR), Italy. At present, Rinaldi is Group Leader of the Unit Advanced Therapies in Preclinical Research and Head of the CNR Commissioned Project Technological Advances in Immunotherapy at the Institute of Translational Pharmacology, CNR. Her major scientific areas include molecular pathology, experimental oncology, and immunotherapy. Her research interests focus on development of innovative medicinal products and protocols for advanced therapies (DNA vaccination and gene therapy) intended for clinical application; preclinical protocols of genetic immunization for anticancer therapy and/or prevention; and combined therapeutic protocols (immunochemotherapy). Her scientific activity is documented by more than 60 articles, published in peer-reviewed journals with impact factor and indexed in PubMed. She is the author of several book chapters and invited reviews. She is Coinventor of US patents (USPTO) and principal investigator of several grants related to biotechnology applications in medicine. She is a member of the editorial boards and peer Reviewer for several scientific journals.
Biography Updated on 30 April 2015